You just read:

Morphotek®, Inc. Announces an Agreement with Fujirebio Diagnostics, Inc. to Commercialize the CA125 II Assay as a Companion Diagnostic for Farletuzumab®

News provided by

Morphotek, Inc.

Sep 05, 2017, 10:00 ET